Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
2027 | 5415 | 39.5 | 76% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
11 | 4 | NEUROSCIENCES//CLINICAL NEUROLOGY//NEUROL | 1112395 |
209 | 3 | GHRELIN//ADRENOMEDULLIN//NEUROPEPTIDE Y | 51926 |
2027 | 2 | PACAP//PITUITARY ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE//VIP | 5415 |
1356 | 1 | PACAP//PITUITARY ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE//VIP | 2700 |
12837 | 1 | HELODERMIN//VIP RECEPTOR//VASOACTIVE INTESTINAL PEPTIDE | 877 |
15342 | 1 | PREPRO VIP MESSENGER RNA//VIP PRECURSOR//CNRS ERA 484 | 717 |
20289 | 1 | SECRETIN RECEPTOR//SECRETIN//SECRETIN ANALOGUES | 467 |
21929 | 1 | GASTRIC SODIUM MONITOR//ACETYLCHOLINESTERASE POSITIVE NERVE//HUMAN VALVE STUDY | 400 |
26458 | 1 | ADAMS SUPER BRAIN STUDIES//LILY AVRAHAM GILDOR CHAIR INVEST GROWTH TORS//ACTIVITY DEPENDENT NEUROPROTECTIVE PROTEIN | 254 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | PACAP | authKW | 2456911 | 11% | 74% | 592 |
2 | PITUITARY ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE | authKW | 873065 | 4% | 74% | 209 |
3 | VIP | authKW | 812230 | 7% | 40% | 359 |
4 | VASOACTIVE INTESTINAL PEPTIDE | authKW | 573702 | 6% | 30% | 337 |
5 | US J AN BIOMED S | address | 317608 | 1% | 78% | 72 |
6 | PITUITARY ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE PACAP | authKW | 303065 | 1% | 79% | 68 |
7 | SECT DEV MOL PHARMACOL | address | 273953 | 1% | 90% | 54 |
8 | HEBERT | address | 238865 | 1% | 76% | 56 |
9 | PAC1 RECEPTOR | authKW | 205899 | 1% | 83% | 44 |
10 | VIP RECEPTOR | authKW | 198461 | 1% | 70% | 50 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Endocrinology & Metabolism | 26915 | 28% | 0% | 1498 |
2 | Neurosciences | 11012 | 28% | 0% | 1495 |
3 | Biochemistry & Molecular Biology | 5612 | 29% | 0% | 1593 |
4 | Physiology | 5575 | 12% | 0% | 641 |
5 | Pharmacology & Pharmacy | 5162 | 20% | 0% | 1079 |
6 | Cell Biology | 1088 | 9% | 0% | 499 |
7 | Gastroenterology & Hepatology | 712 | 4% | 0% | 231 |
8 | Medicine, Research & Experimental | 591 | 5% | 0% | 275 |
9 | Immunology | 402 | 6% | 0% | 327 |
10 | Biophysics | 331 | 4% | 0% | 215 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | US J AN BIOMED S | 317608 | 1% | 78% | 72 |
2 | SECT DEV MOL PHARMACOL | 273953 | 1% | 90% | 54 |
3 | HEBERT | 238865 | 1% | 76% | 56 |
4 | ADAMS SUPER BRAIN STUDIES | 136977 | 0% | 90% | 27 |
5 | LILY AVRAHAM GILDOR CHAIR INVEST GROWTH TORS | 109129 | 0% | 88% | 22 |
6 | PTE MTA LENDULET PAC TEAM | 102819 | 0% | 79% | 23 |
7 | SPORTBIOL | 74044 | 0% | 77% | 17 |
8 | NEUROHUMORAL REGULAT GRP | 61986 | 0% | 50% | 22 |
9 | EXPT ZOOL NEUROBIOL | 57081 | 1% | 35% | 29 |
10 | MOL NEUROPHARMACOL | 51251 | 1% | 11% | 80 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | PEPTIDES | 95252 | 7% | 4% | 385 |
2 | REGULATORY PEPTIDES | 85585 | 5% | 6% | 268 |
3 | JOURNAL OF MOLECULAR NEUROSCIENCE | 68588 | 3% | 7% | 182 |
4 | NEUROPEPTIDES | 18660 | 2% | 4% | 92 |
5 | ANNALS OF THE NEW YORK ACADEMY OF SCIENCES | 17507 | 7% | 1% | 355 |
6 | BIOMEDICAL RESEARCH-TOKYO | 10441 | 1% | 3% | 72 |
7 | ENDOCRINOLOGY | 4057 | 3% | 1% | 137 |
8 | NEUROENDOCRINOLOGY | 3524 | 1% | 1% | 54 |
9 | ADVANCES IN NEUROIMMUNOLOGY | 3317 | 0% | 6% | 10 |
10 | NEUROSCIENCE LETTERS | 1612 | 2% | 0% | 99 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | PACAP | 2456911 | 11% | 74% | 592 | Search PACAP | Search PACAP |
2 | PITUITARY ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE | 873065 | 4% | 74% | 209 | Search PITUITARY+ADENYLATE+CYCLASE+ACTIVATING+POLYPEPTIDE | Search PITUITARY+ADENYLATE+CYCLASE+ACTIVATING+POLYPEPTIDE |
3 | VIP | 812230 | 7% | 40% | 359 | Search VIP | Search VIP |
4 | VASOACTIVE INTESTINAL PEPTIDE | 573702 | 6% | 30% | 337 | Search VASOACTIVE+INTESTINAL+PEPTIDE | Search VASOACTIVE+INTESTINAL+PEPTIDE |
5 | PITUITARY ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE PACAP | 303065 | 1% | 79% | 68 | Search PITUITARY+ADENYLATE+CYCLASE+ACTIVATING+POLYPEPTIDE+PACAP | Search PITUITARY+ADENYLATE+CYCLASE+ACTIVATING+POLYPEPTIDE+PACAP |
6 | PAC1 RECEPTOR | 205899 | 1% | 83% | 44 | Search PAC1+RECEPTOR | Search PAC1+RECEPTOR |
7 | VIP RECEPTOR | 198461 | 1% | 70% | 50 | Search VIP+RECEPTOR | Search VIP+RECEPTOR |
8 | PACAP RECEPTOR | 196063 | 1% | 87% | 40 | Search PACAP+RECEPTOR | Search PACAP+RECEPTOR |
9 | PAC1 | 169146 | 1% | 61% | 49 | Search PAC1 | Search PAC1 |
10 | VPAC1 RECEPTOR | 159326 | 1% | 91% | 31 | Search VPAC1+RECEPTOR | Search VPAC1+RECEPTOR |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | VAUDRY, D , FALLUEL-MOREL, A , BOURGAULT, S , BASILLE, M , BUREL, D , WURTZ, O , FOURNIER, A , CHOW, BKC , HASHIMOTO, H , GALAS, L , ET AL (2009) PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE AND ITS RECEPTORS: 20 YEARS AFTER THE DISCOVERY.PHARMACOLOGICAL REVIEWS. VOL. 61. ISSUE 3. P. 283 -357 | 1023 | 77% | 353 |
2 | VAUDRY, D , GONZALEZ, BJ , BASILLE, M , YON, L , FOURNIER, A , VAUDRY, H , (2000) PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE AND ITS RECEPTORS: FROM STRUCTURE TO FUNCTIONS.PHARMACOLOGICAL REVIEWS. VOL. 52. ISSUE 2. P. 269 -324 | 639 | 76% | 815 |
3 | DICKSON, L , FINLAYSON, K , (2009) VPAC AND PAC RECEPTORS: FROM LIGANDS TO FUNCTION.PHARMACOLOGY & THERAPEUTICS. VOL. 121. ISSUE 3. P. 294 -316 | 247 | 79% | 157 |
4 | SHERWOOD, NM , KRUECKL, SL , MCRORY, JE , (2000) THE ORIGIN AND FUNCTION OF THE PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP)/GLUCAGON SUPERFAMILY.ENDOCRINE REVIEWS. VOL. 21. ISSUE 6. P. 619 -670 | 351 | 59% | 467 |
5 | GONZALEZ, BJ , BASILLE, M , VAUDRY, D , FOURNIER, A , VAUDRY, H , (1998) PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE.ANNALES D ENDOCRINOLOGIE. VOL. 59. ISSUE 5. P. 364 -405 | 353 | 81% | 16 |
6 | SOMOGYVARI-VIGH, A , REGLODI, D , (2004) PITUITARY ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE: A POTENTIAL NEUROPROTECTIVE PEPTIDE.CURRENT PHARMACEUTICAL DESIGN. VOL. 10. ISSUE 23. P. 2861-2889 | 235 | 79% | 151 |
7 | REGLODI, D , KISS, P , LUBICS, A , TAMAS, A , (2011) REVIEW ON THE PROTECTIVE EFFECTS OF PACAP IN MODELS OF NEURODEGENERATIVE DISEASES IN VITRO AND IN VIVO.CURRENT PHARMACEUTICAL DESIGN. VOL. 17. ISSUE 10. P. 962-972 | 157 | 90% | 55 |
8 | HARMAR, AJ , FAHRENKRUG, J , GOZES, I , LABURTHE, M , MAY, V , PISEGNA, JR , VAUDRY, D , VAUDRY, H , WASCHEK, JA , SAID, SI , (2012) PHARMACOLOGY AND FUNCTIONS OF RECEPTORS FOR VASOACTIVE INTESTINAL PEPTIDE AND PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE: IUPHAR REVIEW 1.BRITISH JOURNAL OF PHARMACOLOGY. VOL. 166. ISSUE 1. P. 4 -17 | 145 | 84% | 82 |
9 | DELGADO, M , POZO, D , GANEA, D , (2004) THE SIGNIFICANCE OF VASOACTIVE INTESTINAL PEPTIDE IN IMMUNOMODULATION.PHARMACOLOGICAL REVIEWS. VOL. 56. ISSUE 2. P. 249 -290 | 247 | 51% | 213 |
10 | SEABORN, T , MASMOUDI-KOULI, O , FOURNIER, A , VAUDRY, H , VAUDRY, D , (2011) PROTECTIVE EFFECTS OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AGAINST APOPTOSIS.CURRENT PHARMACEUTICAL DESIGN. VOL. 17. ISSUE 3. P. 204-214 | 139 | 84% | 34 |
Classes with closest relation at Level 2 |